Kevin Scanlon

Kevin Scanlon

Northeastern University
D'Amore-McKim School of Business

Dr. Kevin Scanlon received his Ph.D. in Molecular Biology at the University of London. His career spans roles in academic medicine, senior management in the pharmaceutical industry and biotech companies, as well as an individual investor. Dr. Scanlon was identified by LA Techweek in 2013 as an individual impacting the Los Angeles business and the technology landscape on a significant scale.
Dr. Scanlon served as the Chairman of Pasadena Angels Investment Group, ~100 investors funded over 50 companies for $9.0 MM over 2 years. He has been CEO of four biotechnology companies, including Melanoma Diagnostics, which was sold to Myriad Genetics. At Berlex-Schering AG (Berlin, Germany), he was responsible for the genomic and cancer programs in the US, Europe and Asia.
Dr. Scanlon’s notable academic achievements include: Leukemia Society Scholar, Paul Martini Medical (Cancer) Research Prize (Germany), Co-Founder and Editor of the Nature Journal “Cancer Gene Therapy”, President of the International Society of Cell and Gene Therapy, co-authoring 135 peer-reviewed scientific articles and nine medical books. Dr. Scanlon also holds seven issued US Patents.